Skip to main content
Terug
Watch Compare

Dermata Therapeutics, Inc.

Datakwaliteit: 83%
Ook genoteerd als DRMAW Nasdaq
DRMA
Nasdaq Manufacturing Chemicals
€ 1,22
▲ € 0,01 (0,83%)
Marktkapitalisatie: 4,87 M
Prijs
€ 1,21
Marktkapitalisatie
4,87 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -7,76 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-157,89%
Onder sectorgemiddelde (-53,34%)
ROIC-104,87%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current RatioN/A
Interest CoverageN/A

Waardering

PE (TTM)
-0,64
Boven sectorgemiddelde (-1,47)
P/B Ratio1,23
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -0,6 -1,5
P/B 1,2 1,6
ROE % -157,9 -53,3
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

1 analist
Strong Buy
Huidig
€ 1,22
+227.9%
Koersdoel
€ 4,00
€ 4,00
€ 4,00
€ 4,00
Vooruitzicht
Forward WPA -€ 1,49
Omzet Sch. 750.000,0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 1,49
-€ 1,49 – -€ 1,49
 750.000,0 1
FY2026 -€ 2,20
-€ 2,20 – -€ 2,20
 100.000,0 1

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 1,54 -€ 1,52 +1,3%
Q32025 -€ 1,59 -€ 1,65 -3,8%
Q22025 -€ 2,90 -€ 1,66 +42,8%
Q12025 -€ 4,50 -€ 4,50 0,0%

ETFs Holding This Stock

AVSE logo AVSE Avantis Responsible Emerging Markets Equity ETF
0,01% weight
AVES logo AVES Avantis Emerging Markets Value ETF
0,00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -7,56 M
ROE -157,89% ROA -129,07%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -7,76 M
ROIC -104,87% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio N/A
Interest Coverage N/A Asset Turnover N/A
Working Capital N/A Tangible Book Value 3,96 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,64 Forward P/E N/A
P/B Ratio 1,23 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -159,40%
Market Cap 4,87 M Enterprise Value 202.666,0
Per Share
EPS (Diluted TTM) -8,16 Revenue / Share N/A
FCF / Share -1,93 OCF / Share -1,93
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 102,63%
SBC-Adj. FCF -7,89 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -7,56 M -12,29 M -7,79 M -9,61 M -7,90 M
EPS (Diluted) -8,16 -8,03 — — —
Gross Profit — — — — —
Operating Income -7,77 M -12,51 M -8,04 M -9,67 M -7,86 M
EBITDA — — — — —
R&D Expenses 2,93 M 8,20 M 4,07 M 5,65 M 3,46 M
SG&A Expenses 4,84 M — — — —
D&A — — — — 0,0
Interest Expense — — — 63.573,0 45.613,0
Income Tax — 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 7,86 M 3,53 M 7,98 M 6,94 M 11,62 M
Total Liabilities 1,64 M 1,97 M 1,62 M 922.634,0 1,52 M
Shareholders' Equity 6,22 M 1,56 M 6,36 M 6,02 M 10,11 M
Total Debt — — — — —
Cash & Equivalents 7,52 M — — 6,24 M 10,80 M
Current Assets — — — — 11,62 M
Current Liabilities — — — — 1,52 M